| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Alternative Names | PROKR2, PKR2, G-protein coupled receptor 73-like 1, Gpr73l1, Gpr73b, G-protein coupled receptor I5E |
| Clonality | |
| Conjugate | |
| Host | |
| Isotype | |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
Overview
Anti-Prokineticin Receptor 2 (extracellular) Antibody is an antibody targeting PROKR2, PKR2, G-protein coupled receptor 73-like 1, Gpr73l1, Gpr73b, G-protein coupled receptor I5E Polyclonal raised in Rabbit (Unconjugated). This antibody is commonly used in IF, IFC, IHC, LCI, WB to detect, localize, or compare expression of the target across samples.
Key elements and design rationale
- Target: PROKR2, PKR2, G-protein coupled receptor 73-like 1, Gpr73l1, Gpr73b, G-protein coupled receptor I5E (also reported as PROKR2, PKR2, G-protein coupled receptor 73-like 1, Gpr73l1, Gpr73b, G-protein coupled receptor I5E).
- Immunogen/epitope region: Extracellular, N-terminus.
- Homology note: Mouse - 11/13 amino acid residues identical; human - 9/13 amino acid residues identical (informative for cross-species interpretation).
- Species reactivity (as provided): Rat, Mouse.
- KO-validated: yes (validation context may be assay-dependent).
- Lot quality control (as provided): Western blot analysis.
- Peptide confirmation: Confirmed by amino acid analysis and mass spectrometry.
- Blocking peptide: Available for antigen preadsorption control where appropriate.
These attributes help researchers interpret whether signal reflects the intended target in a given assay and sample context.
Biological background
The Prokineticins (PK1 and PK2) are a pair of cysteine-rich secreted peptides with broad physiological functions including gastrointestinal motility, angiogenesis, hematopoiesis and circadian rhythms regulation.The biological effects of PK1 and PK2 are mediated by two highly homologous receptors termed Prokineticin receptor 1 (PKR1) and Prokineticin receptor 2 (PKR2) that belong to the 7-transmembrane domain, G-protein coupled receptor (GPCR) superfamily. Both PK ligands activate the two PK receptors with similar potency.1PKR2 receptors couple to Gq/G11 proteins leading to phospholipase C activation, inositol phosphate production and calcium mobilization.The distribution of PKR2 is relatively restricted with high expression levels in the brain, spinal cord and dorsal root ganglions, in organs of the reproductive system and in endocrine tissues such as the thyroid, pituitary and adrenal glands.1The PK2 ligand has been shown to be involved in the regulation of circadian rhythms of physiological and behavioral processes in mammals, probably through signaling via PKR2 which is highly expressed in the suprachiasmatic nucleus (SCN), an area of the brain that controls circadian rhythm processes.2In addition, loss-of-function mutations in the PKR2 gene have been associated with Kallmann Syndrome, a condition characterized by idiopathic hypogonadotropic hypogonadism (IHH) in combination with anosmia, a compromised sense of smell.3
Research relevance and current trends
- Comparing target expression across perturbations, genotypes, or treatment conditions.
- Interpreting localization shifts alongside pathway or phenotypic readouts.
- Using orthogonal controls (KO/KD, peptide competition, isotype concepts) to support conclusions.
Common research applications
- Western blot (WB): compare target abundance/size across lysates and conditions; consider isoforms/PTMs.
- Immunohistochemistry (IHC): examine spatial distribution in tissue and relate signal to cell-type composition.
- Immunofluorescence/ICC: assess subcellular localization and co-localization with markers in cells or sections.
- Flow cytometry (direct/indirect): quantify target-positive populations and shifts in expression across subsets.
- Live cell imaging (LCI): support extracellular-epitope detection on non-permeabilized cells when appropriate.
Interpretation typically benefits from comparing matched sample sets (e.g., treated vs control, WT vs KO/KD) and using orthogonal readouts where feasible.
Notes for experimental interpretation
- Isoforms and post-translational modifications can shift apparent molecular weight or epitope accessibility across samples.
- Cross-species signal may depend on epitope conservation; consult the provided homology note when selecting models.
- Permeabilization, fixation, and antigen retrieval can change accessibility of intracellular vs extracellular epitopes.
- Conceptual control: antigen preadsorption (blocking peptide) can help assess signal dependence on the immunogen region.
- Conceptual control: KO/KD samples provide orthogonal support for target assignment when available.
- Provided control suggestions: Negative control: BLP-PR042.
- Application notes: see product-specific dilution/usage notes and control concepts provided in the dataset.
Application abbreviations: CBE- Cell-based ELISA, FC- Flow cytometry, ICC- Immunocytochemistry, IE- Indirect ELISA, IF- Immunofluorescence, IFC- Indirect flow cytometry, IHC- Immunohistochemistry, IP- Immunoprecipitation, LCI- Live cell imaging, N- Neutralization, WB- Western blot. Species abbreviations: H- Human, M- Mouse, R- Rat.
Recommended controls: Blocking peptide: BLP-PR042; Negative control: BLP-PR042.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
